Aims We conducted a systematic review and meta-analysis to assess various antidiabetic
agents' association with mortality in patients with type 2 diabetes (T2DM) who have
coronavirus disease 2019 (COVID-19). Methods We performed comprehensive literature
retrieval from the date of inception until February 2, 2021, in medical databases (PubMed,
Web of Science, Embase, and Cochrane Library), regarding mortality outcomes in patients
with T2DM who have COVID-19. Pooled OR and 95% CI data were used to assess …

Methods Eligible studies for inclusion in this updated meta-analysis were cohort studies that
enrolled T2DM patients with COVID-19 and estimated the COVID-19 mortality risk of use of
DPP4i, SGLT2i, or GLP1RA, compared to no use of DPP4i, SGLT2i, or GLP1RA,
respectively. The comparison of SGLT2i/GLP1RA use versus no SGLT2i/GLP1RA use
included that of SGLT2i/GLP1RA use versus DPP4i use, whereas the comparison of DPP4i
use versus no DPP4i use did not include that of DPP4i use versus SGLT2i/GLP1RA use …